Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

idrabiotaparinux

 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

BiotinOligosaccharides
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2014
Review
2014
Synthetic oligosaccharides as active pharmaceutical ingredients: lessons learned from the full synthesis of one heparin derivative on a large scale.
Covering: up to November 2013. Heparin and heparan sulfate are natural polysaccharides with strong structural variations, which… Expand
Is this relevant?
2014
2014
Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
BACKGROUND Idrabiotaparinux, a long-acting inhibitor of factor Xa, was shown to be effective in the treatment of patients with… Expand
Is this relevant?
2012
2012
Enoxaparin followed by once-weekly idrabiotaparinux versus enoxaparin plus warfarin for patients with acute symptomatic pulmonary embolism: a randomised, double-blind, double-dummy, non-inferiority…
BACKGROUND Treatment of pulmonary embolism with low-molecular-weight heparin and vitamin K antagonists, such as warfarin, is not… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2011
2011
Efficacy and safety of once weekly subcutaneous idrabiotaparinux in the treatment of patients with symptomatic deep venous thrombosis.
BACKGROUND Idraparinux, a long acting inhibitor of factor (F) Xa, is as effective as standard anticoagulant therapy for patients… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
2010
2010
Reversibility of the anti-FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion.
BACKGROUND Idraparinux is an inhibitor of activated factor X (FXa) with a long half-life allowing once-weekly dosing… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2010
2010
Idraparinux and idrabiotaparinux
  • Job Harenberg
  • Expert review of clinical pharmacology
  • 2010
    • Corpus ID: 207209495
Idraparinux is a polymethylated synthetic pentasaccharide that binds to antithrombin with high affinity. Idrabiotaparinux is a… Expand
Is this relevant?
Review
2010
Review
2010
Potential of new anticoagulants in patients with cancer.
Cancer-associated thrombosis is a major cause of morbidity and mortality. Although anticoagulation remains the mainstay for… Expand
  • table 1
  • table 2
Is this relevant?
Review
2009
Review
2009
Development of idraparinux and idrabiotaparinux for anticoagulant therapy.
Idraparinux is an analogue of fondaparinux binding with high affinity to antithrombin. It was designed for weekly, rather than… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
Is this relevant?
2009
2009
The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials.
BACKGROUND Idraparinux, a long-acting synthetic pentasaccharide, is a specific antithrombin-dependent inhibitor of activated… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
2008
2008
Idrabiotaparinux, a Biotinylated Long-Acting Anticoagulant, in the Treatment of Deep Venous Thrombosis (EQUINOX Study): Safety, Efficacy, and Reversibility by Avidin
Idrabiotaparinux is a novel synthetic anticoagulant that links idraparinux, a specific, indirect factor Xa inhibitor, to biotin… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE